<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00542178</url>
  </required_header>
  <id_info>
    <org_study_id>509</org_study_id>
    <secondary_id>N01HC95178-19</secondary_id>
    <nct_id>NCT00542178</nct_id>
  </id_info>
  <brief_title>Evaluating How the Treatments in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Study Affect Diabetic Retinopathy (The ACCORD Eye Study)</brief_title>
  <official_title>Action to Control Cardiovascular Risk in Diabetes (ACCORD) Eye Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Eye Institute (NEI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>National Heart, Lung, and Blood Institute (NHLBI)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Diabetic retinopathy (DR) is an eye disease that can occur in people with diabetes and can
      cause poor vision or blindness. The Action to Control Cardiovascular Risk in Diabetes
      (ACCORD) study is examining the effect of various treatments on cardiovascular disease in
      people with diabetes. This current study will examine the effects of the ACCORD treatments on
      the progression of DR in people participating in the ACCORD study.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      DR is the most common diabetic eye disease and is the leading cause of blindness in adults in
      the United States. It is caused by damage to the blood vessels of the retina, which is the
      light-sensitive outer layer of the eye. Retinal blood vessels are often affected by the high
      blood sugar levels associated with diabetes. Older people have an increased risk of
      developing DR; however, DR is likely to occur earlier and be more severe in anyone who has
      poorly controlled diabetes. Almost everyone who has had diabetes for more than 30 years will
      eventually show signs of DR. Symptoms of DR include poor night vision, seeing spots in front
      of the eyes, blurred vision, and blindness. The ACCORD study is a study that is examining the
      effects of different treatments on cardiovascular disease in people with diabetes.
      Participants in the ACCORD study will receive one of eight different combinations of
      treatment, including blood sugar control, blood pressure control, and cholesterol-controlling
      medication. This study will enroll participants in the ACCORD study and will examine the
      effects of the study treatments on DR. The results from this study may be used to develop new
      treatments to help prevent diabetes-related blindness.

      Study visits will occur at baseline and Year 4. At each study visit, participants will have
      an eye exam and specialized fundus photographs taken of the back of the eye and retina.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2003</start_date>
  <completion_date type="Actual">December 2009</completion_date>
  <primary_completion_date type="Actual">December 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression of Diabetic Retinopathy of at Least 3 Stages on the Early Treatment Diabetic Retinopathy Study (ETDRS) Scale, or Development of Proliferative Diabetic Retinopathy Necessitating Photocoagulation Therapy or Vitrectomy</measure>
    <time_frame>Measured at Year 4</time_frame>
    <description>Diabetic retinopathy status was defined according to the eye with the highest level on the ETDRS Final Severity Scale for Persons, as follows: no diabetic retinopathy, a level of less than 20; mild diabetic retinopathy, a level of 20; moderate nonproliferative diabetic retinopathy (NPDR), a level above 20 but less than 53; severe diabetic retinopathy, a level of 53 but less than 60; and proliferative diabetic retinopathy (PDR), a level of 60 or higher.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Loss of Visual Acuity, Cataract Extraction, or Development or Progression of Macular Edema</measure>
    <time_frame>Measured at Year 4</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">3472</enrollment>
  <condition>Diabetic Retinopathy</condition>
  <arm_group>
    <arm_group_label>Intensive glycemia control</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A strategy of intensive glycemia treatment to HbA1c less than 6%</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard glycemia control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>A strategy of multiple drugs to treat HbA1c to 7.0% - 7.9%</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intensive BP control</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A strategy of BP treatment for SBP less than 120 mm Hg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard BP control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>A strategy of BP treatment for SBP less than 140 mm Hg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fibrate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Blinded fenofibrate + simvastatin 20-40 mg/d</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fibrate Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Blinded placebo + simvastatin 20-40 mg/d</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hypoglycemic Agents</intervention_name>
    <description>Multiple drugs including insulins and oral hypoglycemia agents for HbA1c less than 6%</description>
    <arm_group_label>Intensive glycemia control</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Standard glycemia control</intervention_name>
    <description>A strategy of glycemia drugs for HbA1c 7% - 7.9%</description>
    <arm_group_label>Standard glycemia control</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intensive BP treatment</intervention_name>
    <description>A strategy of multiple BP agents to reduce SBP less than 120 mm Hg</description>
    <arm_group_label>Intensive BP control</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Standard BP control</intervention_name>
    <description>A strategy of BP drugs for SBP less than 140 mm Hg</description>
    <arm_group_label>Standard BP control</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fenofibrate</intervention_name>
    <description>Blinded fenofibrate</description>
    <arm_group_label>Fibrate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Simvastatin</intervention_name>
    <description>Simvastatin 20-40 mg/d</description>
    <arm_group_label>Fibrate</arm_group_label>
    <arm_group_label>Fibrate Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Fibrate Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participating in the ACCORD study

        Exclusion Criteria:

          -  Has had laser photocoagulation for DR

          -  Has had vitrectomy surgery for DR
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Walter T. Ambrosius, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Wake Forest University Health Sciences</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Emily Y. Chew, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Eye Institute (NEI)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Berman Center for Clinical Research</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wake Forest University Health Sciences</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Case Western Reserve University</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106-4951</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Veterans Affairs</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38104-2193</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Washington</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>McMaster University</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8L 2X2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.accordanc.org/</url>
    <description>Click here for the ACCORD Ancillary Studies Web site</description>
  </link>
  <link>
    <url>http://www.accordtrial.org/</url>
    <description>Click here for the ACCORD Study Web site</description>
  </link>
  <reference>
    <citation>Chew EY, Ambrosius WT, Howard LT, Greven CM, Johnson S, Danis RP, Davis MD, Genuth S, Domanski M; ACCORD Study Group. Rationale, design, and methods of the Action to Control Cardiovascular Risk in Diabetes Eye Study (ACCORD-EYE). Am J Cardiol. 2007 Jun 18;99(12A):103i-111i. Epub 2007 Apr 13.</citation>
    <PMID>17599420</PMID>
  </reference>
  <results_reference>
    <citation>ACCORD Study Group; ACCORD Eye Study Group, Chew EY, Ambrosius WT, Davis MD, Danis RP, Gangaputra S, Greven CM, Hubbard L, Esser BA, Lovato JF, Perdue LH, Goff DC Jr, Cushman WC, Ginsberg HN, Elam MB, Genuth S, Gerstein HC, Schubart U, Fine LJ. Effects of medical therapies on retinopathy progression in type 2 diabetes. N Engl J Med. 2010 Jul 15;363(3):233-44. doi: 10.1056/NEJMoa1001288. Epub 2010 Jun 29. Erratum in: N Engl J Med. 2011 Jan 13;364(2):190. N Engl J Med. 2012 Dec 20;367(25):2458.</citation>
    <PMID>20587587</PMID>
  </results_reference>
  <verification_date>November 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 9, 2007</study_first_submitted>
  <study_first_submitted_qc>October 9, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 10, 2007</study_first_posted>
  <results_first_submitted>April 27, 2012</results_first_submitted>
  <results_first_submitted_qc>November 22, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 26, 2013</results_first_posted>
  <last_update_submitted>November 22, 2013</last_update_submitted>
  <last_update_submitted_qc>November 22, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 26, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Type 2 Diabetes Mellitus</keyword>
  <keyword>Cardiovascular Diseases</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Retinal Diseases</mesh_term>
    <mesh_term>Diabetic Retinopathy</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Simvastatin</mesh_term>
    <mesh_term>Fenofibrate</mesh_term>
    <mesh_term>Hypoglycemic Agents</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment for the ACCORD Eye study was restricted to participants recruited as part of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) study. The ACCORD Eye study began in October 2003, with 3472 participants enrolled by February 2006.</recruitment_details>
      <pre_assignment_details>All participants were enrolled in either the intensive or standard glycemia control arms. In addition to inclusion in the glycemia control part of the trial, participants were included as either part of the blood pressure trial (randomized to intensive or standard) OR the lipid trial (fibrate or fibrate placebo).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Intensive Glycemia Control &amp; Intensive Blood Pressure Control</title>
          <description>Intensive Glycemia Control: A strategy of intensive glycemia treatment to HbA1c less than 6%
Intensive Blood Pressure Control: A strategy of BP treatment for SBP less than 120 mm Hg</description>
        </group>
        <group group_id="P2">
          <title>Standard Glycemia Control &amp; Intensive Blood Pressure Control</title>
          <description>Standard Glycemia Control: A strategy of multiple drugs to treat HbA1c to 7.0% - 7.9%
Intensive Blood Pressure Control: A strategy of BP treatment for SBP less than 120 mm Hg</description>
        </group>
        <group group_id="P3">
          <title>Intensive Glycemia Control &amp; Standard Blood Pressure Control</title>
          <description>Intensive Glycemia Control: A strategy of intensive glycemia treatment to HbA1c less than 6%
Standard Blood Pressure Control: A strategy of BP treatment for SBP less than 140 mm Hg</description>
        </group>
        <group group_id="P4">
          <title>Standard Glycemia Control &amp; Standard Blood Pressure Control</title>
          <description>Standard Glycemia Control: A strategy of multiple drugs to treat HbA1c to 7.0% - 7.9%
Standard Blood Pressure Control: A strategy of BP treatment for SBP less than 140 mm Hg</description>
        </group>
        <group group_id="P5">
          <title>Intensive Glycemia Control &amp; Fibrate</title>
          <description>Intensive Glycemia Control: A strategy of intensive glycemia treatment to HbA1c less than 6%
Fibrate: Blinded fenofibrate + simvastatin 20-40 mg/d</description>
        </group>
        <group group_id="P6">
          <title>Standard Glycemia Control &amp; Fibrate</title>
          <description>Standard Glycemia Control: A strategy of multiple drugs to treat HbA1c to 7.0% - 7.9%
Fibrate: Blinded fenofibrate + simvastatin 20-40 mg/d</description>
        </group>
        <group group_id="P7">
          <title>Intensive Glycemia Control &amp; Fibrate Placebo</title>
          <description>Intensive Glycemia Control: A strategy of intensive glycemia treatment to HbA1c less than 6%
Fibrate Placebo: Blinded placebo + simvastatin 20-40 mg/d</description>
        </group>
        <group group_id="P8">
          <title>Standard Glycemia Control &amp; Fibrate Placebo</title>
          <description>Standard Glycemia Control: A strategy of multiple drugs to treat HbA1c to 7.0% - 7.9%
Fibrate Placebo: Blinded placebo + simvastatin 20-40 mg/d</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="390"/>
                <participants group_id="P2" count="412"/>
                <participants group_id="P3" count="382"/>
                <participants group_id="P4" count="370"/>
                <participants group_id="P5" count="464"/>
                <participants group_id="P6" count="495"/>
                <participants group_id="P7" count="493"/>
                <participants group_id="P8" count="466"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="315"/>
                <participants group_id="P2" count="332"/>
                <participants group_id="P3" count="308"/>
                <participants group_id="P4" count="308"/>
                <participants group_id="P5" count="400"/>
                <participants group_id="P6" count="406"/>
                <participants group_id="P7" count="406"/>
                <participants group_id="P8" count="381"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="75"/>
                <participants group_id="P2" count="80"/>
                <participants group_id="P3" count="74"/>
                <participants group_id="P4" count="62"/>
                <participants group_id="P5" count="64"/>
                <participants group_id="P6" count="89"/>
                <participants group_id="P7" count="87"/>
                <participants group_id="P8" count="85"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>did not complete year 4 follow-up</title>
              <participants_list>
                <participants group_id="P1" count="75"/>
                <participants group_id="P2" count="80"/>
                <participants group_id="P3" count="74"/>
                <participants group_id="P4" count="62"/>
                <participants group_id="P5" count="64"/>
                <participants group_id="P6" count="89"/>
                <participants group_id="P7" count="87"/>
                <participants group_id="P8" count="85"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All participants were enrolled in either the intensive or standard glycemia control arms. In addition, participants were included as either part of the blood pressure trial (randomized to intensive or standard) OR the lipid trial (fibrate or fibrate placebo). We completed analysis on participants for whom we had baseline and follow-up data.</population>
      <group_list>
        <group group_id="B1">
          <title>Intensive Glycemia Control</title>
          <description>A strategy of intensive glycemia treatment to HbA1c less than 6%</description>
        </group>
        <group group_id="B2">
          <title>Standard Glycemia Control</title>
          <description>A strategy of multiple drugs to treat HbA1c to 7.0% - 7.9%</description>
        </group>
        <group group_id="B3">
          <title>Intensive BP Control</title>
          <description>A strategy of BP treatment for SBP less than 120 mm Hg</description>
        </group>
        <group group_id="B4">
          <title>Standard BP Control</title>
          <description>A strategy of BP treatment for SBP less than 140 mm Hg</description>
        </group>
        <group group_id="B5">
          <title>Fibrate</title>
          <description>Blinded fenofibrate + simvastatin 20-40 mg/d</description>
        </group>
        <group group_id="B6">
          <title>Fibrate Placebo</title>
          <description>Blinded placebo + simvastatin 20-40 mg/d</description>
        </group>
        <group group_id="B7">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1429"/>
            <count group_id="B2" value="1427"/>
            <count group_id="B3" value="647"/>
            <count group_id="B4" value="616"/>
            <count group_id="B5" value="806"/>
            <count group_id="B6" value="787"/>
            <count group_id="B7" value="5712"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61.6" spread="6.4"/>
                    <measurement group_id="B2" value="61.5" spread="6.3"/>
                    <measurement group_id="B3" value="61.3" spread="6.1"/>
                    <measurement group_id="B4" value="61.5" spread="6.6"/>
                    <measurement group_id="B5" value="61.9" spread="6.2"/>
                    <measurement group_id="B6" value="61.5" spread="6.5"/>
                    <measurement group_id="B7" value="61.6" spread="6.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="538"/>
                    <measurement group_id="B2" value="552"/>
                    <measurement group_id="B3" value="310"/>
                    <measurement group_id="B4" value="279"/>
                    <measurement group_id="B5" value="247"/>
                    <measurement group_id="B6" value="254"/>
                    <measurement group_id="B7" value="2180"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="891"/>
                    <measurement group_id="B2" value="875"/>
                    <measurement group_id="B3" value="337"/>
                    <measurement group_id="B4" value="337"/>
                    <measurement group_id="B5" value="559"/>
                    <measurement group_id="B6" value="533"/>
                    <measurement group_id="B7" value="3532"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Duration of diabetes</title>
          <units>year</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9.8" spread="7.1"/>
                    <measurement group_id="B2" value="10.1" spread="7.2"/>
                    <measurement group_id="B3" value="10.1" spread="7.0"/>
                    <measurement group_id="B4" value="10.3" spread="7.5"/>
                    <measurement group_id="B5" value="9.7" spread="6.8"/>
                    <measurement group_id="B6" value="9.8" spread="7.2"/>
                    <measurement group_id="B7" value="10.0" spread="7.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Previous cardiovascular event</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Previous cardiovascular event</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="452"/>
                    <measurement group_id="B2" value="443"/>
                    <measurement group_id="B3" value="180"/>
                    <measurement group_id="B4" value="197"/>
                    <measurement group_id="B5" value="263"/>
                    <measurement group_id="B6" value="255"/>
                    <measurement group_id="B7" value="1790"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No previous cardiovascular event</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="977"/>
                    <measurement group_id="B2" value="984"/>
                    <measurement group_id="B3" value="467"/>
                    <measurement group_id="B4" value="419"/>
                    <measurement group_id="B5" value="543"/>
                    <measurement group_id="B6" value="532"/>
                    <measurement group_id="B7" value="3922"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Nonwhite race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="427"/>
                    <measurement group_id="B2" value="433"/>
                    <measurement group_id="B3" value="203"/>
                    <measurement group_id="B4" value="201"/>
                    <measurement group_id="B5" value="222"/>
                    <measurement group_id="B6" value="234"/>
                    <measurement group_id="B7" value="1720"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1002"/>
                    <measurement group_id="B2" value="994"/>
                    <measurement group_id="B3" value="444"/>
                    <measurement group_id="B4" value="415"/>
                    <measurement group_id="B5" value="584"/>
                    <measurement group_id="B6" value="553"/>
                    <measurement group_id="B7" value="3992"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Glycated hemoglobin</title>
          <units>percent</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8.2" spread="1.0"/>
                    <measurement group_id="B2" value="8.3" spread="1.0"/>
                    <measurement group_id="B3" value="8.4" spread="1.1"/>
                    <measurement group_id="B4" value="8.2" spread="1.0"/>
                    <measurement group_id="B5" value="8.2" spread="1.0"/>
                    <measurement group_id="B6" value="8.2" spread="1.0"/>
                    <measurement group_id="B7" value="8.2" spread="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Cholesterol</title>
          <units>mg/dl</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>HDL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42.0" spread="11.4"/>
                    <measurement group_id="B2" value="41.9" spread="11.1"/>
                    <measurement group_id="B3" value="46.3" spread="12.8"/>
                    <measurement group_id="B4" value="46.1" spread="13.8"/>
                    <measurement group_id="B5" value="38.6" spread="7.8"/>
                    <measurement group_id="B6" value="38.5" spread="7.9"/>
                    <measurement group_id="B7" value="41.9" spread="11.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LDL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="100.8" spread="33.4"/>
                    <measurement group_id="B2" value="100.7" spread="32.1"/>
                    <measurement group_id="B3" value="107.4" spread="37.0"/>
                    <measurement group_id="B4" value="104.1" spread="33.5"/>
                    <measurement group_id="B5" value="96.5" spread="29.7"/>
                    <measurement group_id="B6" value="97.0" spread="30.1"/>
                    <measurement group_id="B7" value="100.7" spread="32.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Triglycerides</title>
          <units>mg/dl</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="196.1" spread="157.8"/>
                    <measurement group_id="B2" value="194" spread="167.3"/>
                    <measurement group_id="B3" value="200.7" spread="175.5"/>
                    <measurement group_id="B4" value="204.7" spread="240.3"/>
                    <measurement group_id="B5" value="190.1" spread="111.3"/>
                    <measurement group_id="B6" value="187.9" spread="112.4"/>
                    <measurement group_id="B7" value="195.1" spread="162.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Blood pressure</title>
          <units>mm Hg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>Systolic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="134.3" spread="16.6"/>
                    <measurement group_id="B2" value="134.7" spread="17.4"/>
                    <measurement group_id="B3" value="138.0" spread="16.7"/>
                    <measurement group_id="B4" value="139.0" spread="14.7"/>
                    <measurement group_id="B5" value="131.5" spread="17.0"/>
                    <measurement group_id="B6" value="131.1" spread="17.5"/>
                    <measurement group_id="B7" value="134.5" spread="17.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diastolic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="74.9" spread="10.3"/>
                    <measurement group_id="B2" value="75.0" spread="10.6"/>
                    <measurement group_id="B3" value="76.3" spread="10.5"/>
                    <measurement group_id="B4" value="76.8" spread="9.9"/>
                    <measurement group_id="B5" value="73.7" spread="10.5"/>
                    <measurement group_id="B6" value="73.6" spread="10.5"/>
                    <measurement group_id="B7" value="74.9" spread="10.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Urinary albumin:creatinine ratio</title>
          <units>albumin (mg/dL): creatinin (g/dL)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="69.5" spread="2228.9"/>
                    <measurement group_id="B2" value="74.0" spread="275.3"/>
                    <measurement group_id="B3" value="62.5" spread="197.6"/>
                    <measurement group_id="B4" value="79.2" spread="269.9"/>
                    <measurement group_id="B5" value="62.3" spread="180.2"/>
                    <measurement group_id="B6" value="83.2" spread="331.5"/>
                    <measurement group_id="B7" value="71.8" spread="253.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>BMI</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32.4" spread="5.5"/>
                    <measurement group_id="B2" value="32.5" spread="5.4"/>
                    <measurement group_id="B3" value="32.7" spread="5.7"/>
                    <measurement group_id="B4" value="32.2" spread="5.3"/>
                    <measurement group_id="B5" value="32.3" spread="5.5"/>
                    <measurement group_id="B6" value="32.6" spread="5.4"/>
                    <measurement group_id="B7" value="32.4" spread="5.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Visual acuity</title>
          <description>Visual acuity is defined as a mean of the acuity scores for both eyes of 74 to 78 letters (the approximate Snellen equivalent of 20/30)</description>
          <units>letters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="75.9" spread="10.4"/>
                    <measurement group_id="B2" value="75.9" spread="10.0"/>
                    <measurement group_id="B3" value="75.6" spread="10.3"/>
                    <measurement group_id="B4" value="75.5" spread="10.2"/>
                    <measurement group_id="B5" value="76.2" spread="9.7"/>
                    <measurement group_id="B6" value="76.2" spread="10.7"/>
                    <measurement group_id="B7" value="75.9" spread="10.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Smoking status</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Never smoked</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="581"/>
                    <measurement group_id="B2" value="607"/>
                    <measurement group_id="B3" value="279"/>
                    <measurement group_id="B4" value="263"/>
                    <measurement group_id="B5" value="313"/>
                    <measurement group_id="B6" value="333"/>
                    <measurement group_id="B7" value="2376"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Former smoker</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="657"/>
                    <measurement group_id="B2" value="623"/>
                    <measurement group_id="B3" value="279"/>
                    <measurement group_id="B4" value="276"/>
                    <measurement group_id="B5" value="373"/>
                    <measurement group_id="B6" value="352"/>
                    <measurement group_id="B7" value="2560"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Current smoker</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="191"/>
                    <measurement group_id="B2" value="196"/>
                    <measurement group_id="B3" value="89"/>
                    <measurement group_id="B4" value="77"/>
                    <measurement group_id="B5" value="119"/>
                    <measurement group_id="B6" value="102"/>
                    <measurement group_id="B7" value="774"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Diabetic retinopathy status</title>
          <description>Diabetic retinopathy status was defined according to the eye with the highest level on the ETDRS Final Severity Scale for Persons, as follows: no diabetic retinopathy, a level of less than 20; mild diabetic retinopathy, a level of 20; moderate nonproliferative diabetic retinopathy (NPDR), a level above 20 but less than 53; severe diabetic retinopathy, a level of 53 but less than 60; and proliferative diabetic retinopathy (PDR), a level of 60 or higher.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>None</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="729"/>
                    <measurement group_id="B2" value="721"/>
                    <measurement group_id="B3" value="328"/>
                    <measurement group_id="B4" value="295"/>
                    <measurement group_id="B5" value="429"/>
                    <measurement group_id="B6" value="398"/>
                    <measurement group_id="B7" value="2900"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="241"/>
                    <measurement group_id="B2" value="277"/>
                    <measurement group_id="B3" value="105"/>
                    <measurement group_id="B4" value="117"/>
                    <measurement group_id="B5" value="141"/>
                    <measurement group_id="B6" value="155"/>
                    <measurement group_id="B7" value="1036"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate Nonproliferative Diabetic Retinopathy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="443"/>
                    <measurement group_id="B2" value="404"/>
                    <measurement group_id="B3" value="195"/>
                    <measurement group_id="B4" value="198"/>
                    <measurement group_id="B5" value="230"/>
                    <measurement group_id="B6" value="224"/>
                    <measurement group_id="B7" value="1694"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe Nonproliferative Diabetic Retinopathy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="4"/>
                    <measurement group_id="B7" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Proliferative diabetic retinopathy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="4"/>
                    <measurement group_id="B6" value="6"/>
                    <measurement group_id="B7" value="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Progression of Diabetic Retinopathy of at Least 3 Stages on the Early Treatment Diabetic Retinopathy Study (ETDRS) Scale, or Development of Proliferative Diabetic Retinopathy Necessitating Photocoagulation Therapy or Vitrectomy</title>
        <description>Diabetic retinopathy status was defined according to the eye with the highest level on the ETDRS Final Severity Scale for Persons, as follows: no diabetic retinopathy, a level of less than 20; mild diabetic retinopathy, a level of 20; moderate nonproliferative diabetic retinopathy (NPDR), a level above 20 but less than 53; severe diabetic retinopathy, a level of 53 but less than 60; and proliferative diabetic retinopathy (PDR), a level of 60 or higher.</description>
        <time_frame>Measured at Year 4</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Intensive Glycemia Control</title>
            <description>Strategy of intensive glycemia treatment to HbA1c less than 6%</description>
          </group>
          <group group_id="O2">
            <title>Standard Glycemia Control</title>
            <description>Strategy of multiple drugs to treat HbA1c to 7.0% - 7.9%</description>
          </group>
          <group group_id="O3">
            <title>Intensive Blood Pressure Control</title>
            <description>A strategy of BP treatment for SBP less than 120 mmHg</description>
          </group>
          <group group_id="O4">
            <title>Standard Blood Pressure Control</title>
            <description>Strategy of BP treatment for SBP less than 140 mmHg</description>
          </group>
          <group group_id="O5">
            <title>Fenofibrate + Simvastatin Therapy</title>
            <description>Blinded fenofibrate + simvastatin 20-40 mg/d</description>
          </group>
          <group group_id="O6">
            <title>Placebo + Simvastatin Therapy</title>
            <description>Blinded placebo + simvastatin 20-40 mg/d</description>
          </group>
        </group_list>
        <measure>
          <title>Progression of Diabetic Retinopathy of at Least 3 Stages on the Early Treatment Diabetic Retinopathy Study (ETDRS) Scale, or Development of Proliferative Diabetic Retinopathy Necessitating Photocoagulation Therapy or Vitrectomy</title>
          <description>Diabetic retinopathy status was defined according to the eye with the highest level on the ETDRS Final Severity Scale for Persons, as follows: no diabetic retinopathy, a level of less than 20; mild diabetic retinopathy, a level of 20; moderate nonproliferative diabetic retinopathy (NPDR), a level above 20 but less than 53; severe diabetic retinopathy, a level of 53 but less than 60; and proliferative diabetic retinopathy (PDR), a level of 60 or higher.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1429"/>
                <count group_id="O2" value="1427"/>
                <count group_id="O3" value="647"/>
                <count group_id="O4" value="616"/>
                <count group_id="O5" value="806"/>
                <count group_id="O6" value="787"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="104"/>
                    <measurement group_id="O2" value="149"/>
                    <measurement group_id="O3" value="67"/>
                    <measurement group_id="O4" value="54"/>
                    <measurement group_id="O5" value="52"/>
                    <measurement group_id="O6" value="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Our recruitment goal for the ACCORD Eye study was set in order to achieve a statistical power of 88% to detect a 15% relative reduction with intensive glycemic control as compared with standard glycemic control</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.003</p_value>
            <method>Regression, Logistic</method>
            <method_desc>Comparisons made using likelihood-ratio tests from logistic-regression models with adjustment for same study-design factors used in ACCORD analysis</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.67</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.51</ci_lower_limit>
            <ci_upper_limit>0.87</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Our recruitment goal for the ACCORD Eye study was set in order to achieve a statistical power of 80% to detect a 20% relative reduction with intensive blood pressure control as compared with standard blood pressure control</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.29</p_value>
            <method>Regression, Logistic</method>
            <method_desc>Comparisons made using likelihood-ratio tests from logistic-regression models with adjustment for same study-design factors used in ACCORD analysis</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.23</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.84</ci_lower_limit>
            <ci_upper_limit>1.79</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Our recruitment goal for the ACCORD Eye study was set in order to achieve a statistical power of 91% to detect a 20% relative reduction with lipid control with a statin and fenofibrate as compared with lipid control with a statin alone</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.006</p_value>
            <method>Regression, Logistic</method>
            <method_desc>Comparisons made using likelihood-ratio tests from logistic-regression models with adjustment for same study-design factors used in ACCORD analysis</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.60</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.42</ci_lower_limit>
            <ci_upper_limit>0.87</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Loss of Visual Acuity, Cataract Extraction, or Development or Progression of Macular Edema</title>
        <time_frame>Measured at Year 4</time_frame>
        <posting_date>05/2013</posting_date>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Entire duration of the study</time_frame>
      <desc>Adverse events were collected as part of the ACCORD main trial. No adverse events were collected as part of the ACCORD-Eye Study.</desc>
      <group_list>
        <group group_id="E1">
          <title>Intensive Glycemia Control</title>
          <description>A strategy of intensive glycemia treatment to HbA1c less than 6%</description>
        </group>
        <group group_id="E2">
          <title>Standard Glycemia Control</title>
          <description>A strategy of multiple drugs to treat HbA1c to 7.0% - 7.9%</description>
        </group>
        <group group_id="E3">
          <title>Intensive BP Control</title>
          <description>A strategy of BP treatment for SBP less than 120 mm Hg</description>
        </group>
        <group group_id="E4">
          <title>Standard BP Control</title>
          <description>A strategy of BP treatment for SBP less than 140 mm Hg</description>
        </group>
        <group group_id="E5">
          <title>Fibrate</title>
          <description>Blinded fenofibrate + simvastatin 20-40 mg/d</description>
        </group>
        <group group_id="E6">
          <title>Fibrate Placebo</title>
          <description>Blinded placebo + simvastatin 20-40 mg/d</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The glycemia trial was stopped early, potentially underestimating the reported effect of glycemia treatment on diabetic retinopathy.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Walter Ambrosius, PhD</name_or_title>
      <organization>Wake Forest University School of Medicine</organization>
      <phone>336-716-6281</phone>
      <email>wambrosi@wakehealth.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

